Drug Shortage Report for BOOSTRIX-POLIO

Last updated on 2025-11-29 History
Report ID 265359
Drug Identification Number 02312557
Brand name BOOSTRIX-POLIO
Common or Proper name Combined diphtheria, tetanus, acellular pertussis (adsorbed) and inactivated poliomyelitis vaccine
Company Name GLAXOSMITHKLINE INC
Market Status MARKETED
Active Ingredient(s) INACTIVATED POLIOVIRUS TYPE I PERTUSSIS TOXOID ADSORBED INACTIVATED POLIOVIRUS TYPE III INACTIVATED POLIOVIRUS TYPE II FILAMENTOUS HAEMAGGLUTININ ADSORBED TETANUS TOXOID ADSORBED PERTACTIN ADSORBED DIPHTHERIA TOXOID ADSORBED
Strength(s) 40D 8MCG 32D 8D 8MCG 5.0LF 2.5MCG 2.5LF
Dosage form(s) SUSPENSION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 10's
ATC code J07CA
ATC description BACTERIAL AND VIRAL VACCINES, COMBINED
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2025-08-13
Estimated end date 2025-11-30
Actual end date 2025-11-28
Shortage status Resolved
Updated date 2025-11-29
Company comments Current shortage impacts private market. Potential for future disruption in public programs.
Health Canada comments
Tier 3 Status No
Company contact information 1-800-387-7374

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v15 2025-11-29 English Compare
v14 2025-11-28 French Compare
v13 2025-11-28 English Compare
v12 2025-09-10 French Compare
v11 2025-09-10 English Compare
v10 2025-09-10 French Compare
v9 2025-09-10 English Compare
v8 2025-09-03 French Compare
v7 2025-09-03 English Compare
v6 2025-08-29 French Compare
v5 2025-08-29 English Compare
v4 2025-08-20 French Compare
v3 2025-08-20 English Compare
v2 2025-08-15 French Compare
v1 2025-08-15 English Compare

Showing 1 to 15 of 15